{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:51:03Z","timestamp":1789156263351,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K17860"],"award-info":[{"award-number":["19K17860"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K09908"],"award-info":[{"award-number":["17K09908"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["HU"],"award-info":[{"award-number":["HU"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.leukres.2019.106273","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T11:31:45Z","timestamp":1574076705000},"page":"106273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Role of cancer immunology in chronic myelogenous leukemia"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-3699","authenticated-orcid":false,"given":"Hiroshi","family":"Ureshino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takero","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2019.106273_bib0005","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Intergroupe Fran\u00e7ais des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques, Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2019.106273_bib0010","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"DADI Trial Group, Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.leukres.2019.106273_bib0015","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2019.106273_bib0020","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106273_bib0025","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2019.106273_bib0030","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2019.106273_bib0035","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.bmt.1701496","article-title":"Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells","volume":"22","author":"Verdonck","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.leukres.2019.106273_bib0040","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1002\/cncr.28328","article-title":"Tolerability and efficacy of pegylated interferon-\u03b1-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia","volume":"119","author":"Johnson-Ansah","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2019.106273_bib0045","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106273_bib0050","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.leukres.2010.04.010","article-title":"Pegylated IFN-\u03b12a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone","volume":"35","author":"Nicolini","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2019.106273_bib0055","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon Alfa-2a in chronic myeloid leukemia","volume":"363","author":"Roche-Lestienne","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2019.106273_bib0060","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/leu.2015.45","article-title":"Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia","volume":"29","author":"Burchert","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2019.106273_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2015.00107","article-title":"Myeloid derived suppressor cells in chronic myeloid leukemia","volume":"5","author":"Giallongo","year":"2015","journal-title":"Front. Oncol."},{"issue":"80-","key":"10.1016\/j.leukres.2019.106273_bib0070","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1126\/science.284.5418.1313","article-title":"Phylogenetic perspectives in innate immunity","volume":"284","author":"Hoffmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.leukres.2019.106273_bib0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1084\/jem.188.1.71","article-title":"Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection","volume":"188","author":"Sourdive","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2019.106273_bib0080","article-title":"The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2019.106273_bib0085","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.celrep.2015.12.090","article-title":"L-selectin is essential for delivery of activated CD8+ t cells to virus-infected organs for protective immunity","volume":"14","author":"Mohammed","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.leukres.2019.106273_bib0090","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2016.67.0893","article-title":"Reduced CD62L expression on t cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia","volume":"35","author":"Sopper","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2019.106273_bib0095","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/44385","article-title":"Two subsets of memory T lymphocytes with distinct homing potentials and effector functions","volume":"401","author":"Sallusto","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2019.106273_bib0100","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood-2009-05-220087","article-title":"The CD8+ memory T-cell state of readiness is actively maintained and reversible","volume":"114","author":"Allam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106273_bib0105","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106273_bib0110","doi-asserted-by":"crossref","first-page":"e1405204","DOI":"10.1080\/2162402X.2017.1405204","article-title":"Deep sequencing of the T cell receptor visualizes reconstitution of T cell immunity in mogamulizumab-treated adult T cell leukemia","volume":"7","author":"Shindo","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.leukres.2019.106273_bib0115","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/bmt.2015.133","article-title":"Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients","volume":"50","author":"Yew","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.leukres.2019.106273_bib0120","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI488","article-title":"Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia","volume":"101","author":"Yotnda","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.leukres.2019.106273_bib0125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1034\/j.1600-065X.2002.18803.x","article-title":"Cancer\/testis antigens: an expanding family of targets for cancer immunotherapy","volume":"188","author":"Scanlan","year":"2002","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.leukres.2019.106273_bib0130","doi-asserted-by":"crossref","first-page":"8210","DOI":"10.4049\/jimmunol.174.12.8210","article-title":"Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy","volume":"174","author":"Gannag\u00e9","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2019.106273_bib0135","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106273_bib0140","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/ijc.21960","article-title":"Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Morita","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2019.106273_bib0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011770","article-title":"PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal","volume":"5","author":"Kanodia","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2019.106273_bib0150","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1038\/bcj.2017.84","article-title":"CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients","volume":"7","author":"Matsushita","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2019.106273_bib0155","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","article-title":"Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies","volume":"111","author":"Rezvani","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106273_bib0160","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3324\/haematol.2010.031674","article-title":"Repeated PR1 and WT1 peptide vaccination in montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies","volume":"96","author":"Rezvani","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2019.106273_bib0165","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1600-0609.2010.01497.x","article-title":"WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient","volume":"85","author":"Oji","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2019.106273_bib0170","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri3801","article-title":"The early history of B cells","volume":"15","author":"Cooper","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.leukres.2019.106273_bib0175","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/0008-5472.CAN-16-0431","article-title":"The emerging role of b cells in tumor immunity","volume":"76","author":"Tsou","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2019.106273_bib0180","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.leukres.2019.106273_bib0185","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.leukres.2019.106273_bib0190","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106273_bib0195","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML","volume":"32","author":"Br\u00fcck","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2019.106273_bib0200","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.leukres.2019.106273_bib0205","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10147-013-0615-9","article-title":"Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients","volume":"19","author":"Zahran","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2019.106273_bib0210","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.leukres.2019.106273_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune effector recovery in chronic myeloid leukemia and treatment-free remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2019.106273_bib0220","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.leukres.2018.01.010","article-title":"Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response\u2014the final results of the D-first study","volume":"66","author":"Najima","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2019.106273_bib0225","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment, clin lymphoma","volume":"18","author":"Okada","year":"2018","journal-title":"Myeloma Leuk."},{"key":"10.1016\/j.leukres.2019.106273_bib0230","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106273_bib0235","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1038\/onc.2008.267","article-title":"NK cells and cancer immunosurveillance","volume":"27","author":"Waldhauer","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2019.106273_bib0240","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bmt.1700933","article-title":"Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"20","author":"Van Rhee","year":"1997","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.leukres.2019.106273_bib0245","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-019-0513-5","article-title":"Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry","author":"L\u00fcbking","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.leukres.2019.106273_bib0250","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2141.1988.tb07628.x","article-title":"Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect","volume":"69","author":"Apperley","year":"1988","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2019.106273_bib0255","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106273_bib0260","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2019.106273_bib0265","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2005-05-1897","article-title":"Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia","volume":"107","author":"Savani","year":"2006","journal-title":"Blood"},{"issue":"80-","key":"10.1016\/j.leukres.2019.106273_bib0270","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.leukres.2019.106273_bib0275","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/eji.1830270313","article-title":"Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structural evidence for new stimulatory and inhibitory pathways","volume":"27","author":"Samaridis","year":"1997","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.leukres.2019.106273_bib0280","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.it.2013.01.003","article-title":"Activating natural cytotoxicity receptors of natural killer cells in cancer and infection","volume":"34","author":"Koch","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.leukres.2019.106273_bib0285","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/0008-5472.CAN-05-2776","article-title":"Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance","volume":"66","author":"Hayashi","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2019.106273_bib0290","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1182\/blood-2010-04-281675","article-title":"Expression patterns of NKG2A, KIR, and CD57 define a process of CD56 dim NK-cell differentiation uncoupled from NK-cell education","volume":"116","author":"Bj\u00f6rkstr\u00f6m","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106273_bib0295","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nri1570","article-title":"MHC class I molecules and KIRs in human history, health and survival","volume":"5","author":"Parham","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.leukres.2019.106273_bib0300","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the \u201cmissing self\u201d: MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol. Today"},{"key":"10.1016\/j.leukres.2019.106273_bib0305","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1600-065X.2006.00458.x","article-title":"Licensing of natural killer cells by self-major histocompatibility complex class I","volume":"214","author":"Yokoyama","year":"2006","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.leukres.2019.106273_bib0310","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature03847","article-title":"Licensing of natural killer cells by host major histocompatibility complex class I molecules","volume":"436","author":"Kim","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2019.106273_bib0315","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri3370","article-title":"Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution","volume":"13","author":"Parham","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.leukres.2019.106273_bib0320","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri2278","article-title":"Cis interactions of immunoreceptors with MHC and non-MHC ligands","volume":"8","author":"Held","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.leukres.2019.106273_bib0325","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3324\/haematol.2013.101931","article-title":"Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells","volume":"99","author":"Torelli","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2019.106273_bib0330","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/ijc.25233","article-title":"The BCR\/ABL-inhibitors Imatinib, nilotinib and dasatinib differentially affect NK cell reactivity","volume":"127","author":"Salih","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2019.106273_bib0335","first-page":"1","article-title":"NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia","volume":"10","author":"Chang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2019.106273_bib0340","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3324\/haematol.2009.008318","article-title":"NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies","volume":"94","author":"Espinoza","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2019.106273_bib0345","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s12185-017-2294-1","article-title":"NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib","volume":"106","author":"Hara","year":"2017","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2019.106273_bib0350","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2567.2010.03398.x","article-title":"Structure\/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations","volume":"132","author":"Campbell","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.leukres.2019.106273_bib0355","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1084\/jem.20152023","article-title":"Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition","volume":"213","author":"Saunders","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2019.106273_bib0360","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ng2035","article-title":"Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1","volume":"39","author":"Martin","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2019.106273_bib0365","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1200\/JCO.2015.64.9558","article-title":"KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to Anti-GD2 monoclonal antibody in patients with neuroblastoma","volume":"34","author":"Forlenza","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2019.106273_bib0370","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1200\/JCO.2016.70.7059","article-title":"KIR3DL1\/ HL A-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation","volume":"35","author":"Boudreau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2019.106273_bib0375","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1097\/01.TP.0000164500.16052.3C","article-title":"Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor","volume":"79","author":"Elmaagacli","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.leukres.2019.106273_bib0380","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1182\/blood-2007-01-065383","article-title":"Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT","volume":"109","author":"Miller","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106273_bib0385","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/bjc.2014.423","article-title":"HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients","volume":"111","author":"Zhao","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.leukres.2019.106273_bib0390","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2019.106273_bib0395","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/leu.2011.180","article-title":"KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib","volume":"26","author":"Marin","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2019.106273_bib0400","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.exphem.2013.01.008","article-title":"Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients","volume":"41","author":"La Nasa","year":"2013","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2019.106273_bib0405","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.exphem.2012.07.007","article-title":"Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia","volume":"40","author":"Kreutzman","year":"2012","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2019.106273_bib0410","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2015-07-655589","article-title":"KIR2DL5B genotype predicts outcomes in CML patients treated with response directed sequential imatinib \/ nilotinib strategy","volume":"126","author":"Yeung","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106273_bib0415","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2012-04-421016","article-title":"Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia","volume":"120","author":"Ali","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106273_bib0420","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1158\/2326-6066.CIR-17-0462","article-title":"Allelic polymorphisms of KIR s and HLA s predict favorable responses to tyrosine kinase inhibitors in CML","volume":"6","author":"Ureshino","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.leukres.2019.106273_bib0425","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20051884","article-title":"Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function","volume":"203","author":"Yawata","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2019.106273_bib0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2019.1638210","article-title":"Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line","volume":"8","author":"Kreutzman","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.leukres.2019.106273_bib0435","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.4049\/jimmunol.181.10.6955","article-title":"Imatinib mesylate inhibits CD4 + CD25 + regulatory t cell activity and enhances active immunotherapy against BCR-ABL \u2212 tumors","volume":"181","author":"Larmonier","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.leukres.2019.106273_bib0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-9-22","article-title":"Effects of nilotinib on regulatory T cells: the dose matters","volume":"9","author":"Fei","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.leukres.2019.106273_bib0445","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1535-7163.MCT-14-0849","article-title":"The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses","volume":"14","author":"Christiansson","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2019.106273_bib0450","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.exphem.2015.08.004","article-title":"Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients","volume":"43","author":"Caocci","year":"2015","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2019.106273_bib0455","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","article-title":"Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia","volume":"330","author":"Italian Cooperative Study Group on Chronic Myeloid Leukemia","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2019.106273_bib0460","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"MM-015 Investigators, Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2019.106273_bib0465","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2019.106273_bib0470","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1111\/bjh.15894","article-title":"Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia","volume":"186","author":"Ross","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2019.106273_bib0475","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/cas.13430","article-title":"Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation","volume":"109","author":"Kumagai","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.leukres.2019.106273_bib0480","first-page":"2935","article-title":"Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib","volume":"15","author":"Jo","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.leukres.2019.106273_bib0485","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/leu.2017.9","article-title":"Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML","volume":"31","author":"Sch\u00fctz","year":"2017","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619307180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619307180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:43:12Z","timestamp":1777488192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619307180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":97,"alternative-id":["S0145212619307180"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106273","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of cancer immunology in chronic myelogenous leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106273"}}